HER-2 positive

P4, N=568, Recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital | Not yet recruiting --> Recruiting

P=N/A, N=200, Recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting --> Recruiting

P3, N=132, Not yet recruiting, Sun Yat-sen University

P2, N=60, Not yet recruiting, Shanghai JMT-Bio Inc.

Luminal B was found to be the predominant molecular subtype. Molecular subtype had a significant association with grade and proliferation index.

Routinely available systemic inflammatory and immune-nutritional biomarkers, particularly LMR, SII, and CAR, are independently associated with pathological and radiological response to neoadjuvant dual anti-HER2 therapy in HER2-positive BC. These findings support the potential role of host-related biomarkers in treatment response prediction, pending prospective validation.

HPLC profiling of 12 commercial batches identified ten common constituents: tetramethylpyrazine, chlorogenic acid, ferulic acid, senkyunolide I, senkyunolide H, 6″-feruloylspinosin, senkyunolide A, n-butylbenzene, ligustilide, and butenylbenzene. Molecular docking indicated that bioactive constituents may modulate ferroptosis via interactions with SLC7A11 and FSP1. The integrated ECI framework offers an efficacy-driven quality control approach for Chuanxiong Rhizoma and supports its dual application to enhance antitumor activity while mitigating trastuzumab-induced cardiotoxicity.

Safety profiles, including cardiac toxicity, were similar between groups. HLX02 demonstrated equivalent efficacy and safety to the originator trastuzumab in this setting, representing a cost-effective treatment alternative.

Following intratumoral administration in nude mice bearing HER2-positive NCI-N87 tumors, MNPs-PMPC-Tmab exhibited higher intratumoral retention than non-antibody-modified controls and remained detectable for up to 72 h. Upon AMF exposure, these nanoparticles elevated tumor temperature to 46 °C and successfully suppressed tumor growth. Collectively, these results demonstrate that surface engineering integrating an antifouling polymer brush with a tumor-targeting antibody is an effective strategy for improving intratumoral retention of magnetic nanoparticles and enhancing therapeutic performance in magnetic hyperthermia.

Patients diagnosed with ILRR after curative treatment for primary BC are at higher risk of subsequent DR, highlighting the need for prompt diagnosis and treatment of ILRR. Moreover, biological recharacterization of ILRR provides potential key prognostic and predictive factors, such as HR loss, allowing personalization of treatment and follow-up after ILRR.

P1/2, N=24, Terminated, Institut Paoli-Calmettes | N=106 --> 24 | Suspended --> Terminated; Drug development withdrawn